Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.

By R. Legro, A. Kunselman, A. Dunaif. American Journal of Medicine, 2001

605 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. (2014, positive): “…present in 70% of patients, most often represented by hypertriglycaeridaemia and low HDL cholesterol levels and small dense LDL cholesterol (LDL-C) particles – atherogenic dyslipidaemia, typical for the states of insulin resistance (170) while LDL-C seems to be more androgen dependent (175, 176).”
Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. (2010, background): “, 1995) and metabolic disturbances (Legro et al., 1999; Legro et al., 2001; Boudreaux et al., 2006; Ehrmann et al., 2006).”
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. (2009, background): “Prevalence of at least one abnormal lipid level (borderline or high) by National Cholesterol Education Program guidelines approaches 70% (207).”
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). (2004, background): “…normal susceptibility to coronary heart disease. and women with PCOS have evidence of dyslipidaemia (Conway et al., 1992; Robinson et al., 1996; Talbott et al., 1998; Legro et al., 2001) and markers of abnormal vascular function (Talbott et al., 2000; Paradisi et al., 2001; Christian et al., 2003).”